SCHEMBL25668993

SCHEMBL25668993

COc1cc2c(cc1OC)CN(C(=O)c1c(O)cc(O)cc1OCc1ccccc1)C2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.51
GPR183 P32249 1/20 0.51
KMT2A Q03164 3/20 0.50
NPC1 O15118 3/20 0.50
AGTR2 P50052 1/20 0.48
MEN1 O00255 2/20 0.47
PDE4B Q07343 1/20 0.46
HCRTR2 O43614 2/20 0.46
RAB9A P51151 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
APP P05067 1/20 0.44
HCRTR1 O43613 1/20 0.44
REV1 Q9UBZ9 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
MDM2 Q00987 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30368419 1.00 CHRNA7 (0.51) CHRNA7GPR183KMT2ANPC1AGTR2
SCHEMBL30368420 0.90 SPR (0.49) MAPT
SCHEMBL25668954 0.90 SPR (0.49) MAPT
SCHEMBL25668992 0.89 HDAC8 (0.44) GPR183APPHDAC8
SCHEMBL30368448 0.89 HDAC8 (0.44) GPR183APPHDAC8
SCHEMBL25668982 0.89 TRAP1 (0.54) CHRNA7GPR183KMT2AMEN1ALDH1A1
SCHEMBL30368285 0.89 TRAP1 (0.54) CHRNA7GPR183KMT2AMEN1ALDH1A1
SCHEMBL30368246 0.86 LMNA (0.48) GPR183NPC1RAB9AHSD17B10HPGD
SCHEMBL25668990 0.86 LMNA (0.48) GPR183NPC1RAB9AHSD17B10HPGD
SCHEMBL24914083 0.85 PTGER1 (0.42) KMT2ANPC1MEN1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115996907-A Inhibitors of MLH1 and/or PMS2 for cancer treatment 奈奥芬莱有限公司 2023-04-21 CN claimed
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT Neophore Limited (GB) 2023-06-15 US disclosed
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT Neophore Limited (GB) 2023-06-15 US disclosed
CN-115996907-A Inhibitors of MLH1 and/or PMS2 for cancer treatment 奈奥芬莱有限公司 2023-04-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT MSH2, PMS2, MSH6 CHRNA7 4696/4885GPR183 2133/4885KMT2A 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.